Prophylaxis for heterotopic ossification after primary total hip arthroplasty: A cohort study between Indomethacin and Meloxicam

Acta Orthopaedica Belgica

Volumn 70, Issue 3, 2004, Pages 240-246

  Van Der Heide, Huub J L ^a,b   Spruit, Maarten ^a,b   Slappendel, Rob ^a,b   Klooster, Niels ^a,b   Van Limbeek, Jacques ^a,c  

^a SINT MAARTENSKLINIEK   (Netherlands)

^b Department of Orthopaedics ^*

^c Alberta Health Services Edmonton Zone   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; BUPIVACAINE; CEFAZOLIN; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MELOXICAM; MORPHINE; NADROPARIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; HETEROTOPIC OSSIFICATION; HIP RADIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PEPTIC ULCER BLEEDING; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; RADIOTHERAPY; SPINAL ANESTHESIA; TOTAL HIP PROSTHESIS; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; CHEMOPREVENTION; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; OBSERVER VARIATION; OSSIFICATION, HETEROTOPIC; PROSPECTIVE STUDIES; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 3042788103     PISSN: 00016462     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Ahrengart L. Periarticular heterotopic ossification after total hip arthroplasty. Risk factors and consequences. Clin Orthop 1991; 263: 49-58.
2. Ahrengart L, Blomgren G, Tornkvist H. Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 1994; 65: 139-141.
3. Ahrengart L, Lindgren U. Functional significance of heterotopic bone formation after total hip arthroplasty. J Arthroplasty 1989; 4: 125-131.
4. Amstutz HC, Fowble VA, Schmalzried TP, Dorey FJ. Short-course indomethacin prevents heterotopic ossification in a high-risk population following total hip arthroplasty. J Arthroplasty 1997; 12: 126-132.
5. Bischoff R, Dunlap J, Carpenter L, DeMouy E, Barrack R. Heterotopic ossification following uncemented total hip arthroplasty. Effect of the operative approach. J Arthroplasty 1994; 9: 641-644.
6. Burssens A, Thiery J, Kohl P, Molderez A, Haazen L. Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. Acta Orthop Belg 1995; 61: 205-211.
7. Celia JP, Salvati EA, Sculco TP. Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty 1988; 3: 229-234.
8. Dahl HK. Kliniske observasjoner. Symposium on hip arthrose. Blindern, MSD, Norway 1975; 37-46.
9. Degner F, Turck D, Pairet M. Meloxicam, Pharmacological, Pharmacokinetic and Clinical Profile. Drugs of today 1998; 34.
10. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (select) trial in osteoarthritis. Br J Rheumatology 1998; 37: 946-951.
11. Dorn U, Grethen C, Effenberger H, Berka H, Ramsauer T, Drekonja T. Indomethacin for prevention of heterotopic ossification after hip arthroplasty. A randomized comparison between 4 and 8 days of treatment. Acta Orthop Scand 1998; 69: 107-110.
12. Eggli S, Rodriguez J, Ganz R. Heterotopic ossification in total hip arthroplasty: The significance for clinical outcome. Acta Orthop Belg 2000; 66: 174-180.
13. Gebuhr P, Soelberg M, Orsnes T, Wilbek H. Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients. Acta Orthop Scand 1991; 62: 226-229.
14. Gebuhr P, Wilbek H, Soelberg M. Naproxen for 8 days can prevent heterotopic ossification after hip arthroplasty. Clin Orthop 1995; 314: 166-169.
15. Hawkey C, Kahan A, Steinbruck K, Alegre C, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatology 1998; 37: 937-945.
16. Hierton C, Blomgren G, Lindgren U. Factors associated with heterotopic bone formation in cemented total hip prostheses. Acta Orthop Scand 1983; 54: 698-702.
17. Kjaersgaard-Andersen P, Nafei A, Teichert G et al. Indomethacin for prevention of heterotopic ossification. A randomized controlled study in 41 hip arthroplasties. Acta Orthop Scand 1993; 64: 639-642.
18. Kjaersgaard-Andersen P, Schmidt SA. Total hip arthroplasty. The role of antiinflammatory medications in the prevention of heterotopic ossification. Clin Orthop. 1991; 263:78-86.
19. Kjaersgaard-Andersen P, Steinke MS, Hougaard K, Sojbjerg JO, Jensen J. Heterotopic bone formation following hip arthroplasty. A retrospective study of 65 bilateral cases. Acta Orthop Scand 1991; 62: 223-225.
20. Knelles D, Barthel T, Karrer A, Kraus U, Eulert J, Kolbl O. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional of single dose irradiation. J Bone Joint Surg 1997; 79-B: 596-602.
21. Kolbl O, Knelles D, Barthel T, Kraus U, Flentje M, Eulert J. Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement. In J Radiat Oncol Biol Phys 1997; 39: 961-966.
22. Koorevaar CT, Hu HP, Lemmens A, van Kampen A. No effective prophylaxis of heterotopic ossification with short-term ibuprofen. Arch Orthop Trauma Surg 1999; 119: 183-185.
23. Kristensen SS, Pedersen P, Pedersen NW, Schmidt SA, Kjaersgaard-Andersen P. Combined treatment with indomethacin and low-dose heparin after total hip replacement. A double-blind placebo-controlled clinical trial. J. Bone Joint Surg 1990; 72-B: 447-449.
24. Lemmens A. Analyse van de radiologische veranderingen rond de totale heupprothese volgens Charnley-Muller. Thesis, Nijmegen, The Netherlands. 1987.
25. Lieberman IH, Moran E, Hastings DE, Bogoch ER. Heterotopic ossification after primary cemented and non-cemented total hip arthroplasty in patients with osteoarthritis and rheumatoid arthritis. Can J Surg 1994; 37: 135-139.
26. Lindholm TS, Viljakka T, Vankka E, Popov L, Lindholm TC. Development of heterotopic ossification around the hip. A long-term follow-up of patients who underwent surgery with two different types of endoprostheses. Arch Orthop Trauma Surg 1986; 105: 263-267.
27. Maloney WJ, Jasty M, Willett C, Mulroy RD, Jr., Harris WH. Prophylaxis for heterotopic bone formation after total hip arthroplasty using low-dose radiation in high-risk patients. Clin. Orthop. 1992; 280: 230-234.
28. Maloney WJ, Krushell RJ, Jasty M, Harris WH. Incidence of heterotopic ossification after total hip replacement: effect of the type of fixation of the femoral component. J Bone Joint Surg 1991; 73-A: 191-193.
29. McMahon JS, Waddell JP, Morton J. Effect of short-course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplasty 1991; 6: 259-264.
30. Nayak KN, Mulliken B, Rorabeck CH, Bourne RB, Woolfrey MR. Prevalence of heterotopic ossification in cemented versus noncemented total hip joint replacement in patients with osteoarthrosis: A randomized clinical trial. Can J Surg 1997; 40: 368-374.
31. Neal B, Rodgers A, Dunn L, Fransen M. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2000; CD001160.
32. Neal BC, Rodgers A, Clark T et al. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta OrthopScand 2000; 71: 122-128.
33. Nollen JG, van Douveren FQ. Ectopic ossification in hip arthroplasty. A retrospective study of predisposing factors in 637 cases. Acta Orthop Scand 1993; 64: 185-187.
34. Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty. A randomized double-blind prospective study of treatment time. Acta Orthop Scand. 1998; 69: 111-115.
35. Purtill JJ, Eng K, Rothman RH, Hozack WJ. Heterotopic ossification. Incidence in cemented versus cementless total hip arthroplasty. J Arthroplasty 1996; 11: 58-63.
36. Ritter MA, Gioe TJ. The effect of indomethacin on para-articular ectopic ossification following total hip arthroplasty. Clin Orthop 1982; 113-117.
37. Schmidt SA, Kjaersgaard-Andersen P, Pedersen NW, Kristensen SS, Pedersen P, Nielsen JB. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg 1988; 70-A: 834-838.
38. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta analysis and systemic review of randomized controlled trials. Am J Med 1999; 107 (suppl 6a): 48s-54s.
39. Sell S, Willms R, Jany R et al. The suppression of heterotopic ossifications: radiation versus NSAID therapy - a prospective study. J Arthroplasty 1998; 13: 854-859.
40. Sneath RJ, Bindi FD, Davies J, Parnell EJ. The effect of pulsed irrigation on the incidence of heterotopic ossification after total hip arthroplasty. J Arthroplasty 2001; 16: 547-551.
41. Sodemann B, Persson PE, Nilsson OS. Prevention of heterotopic ossification by nonsteroid antiinflammatory drugs after total hip arthroplasty. Clin Orthop 1988; 237: 158-163.
42. Testa NN, Mazur KU. Heterotopic ossification after direct lateral approach and transtrochanteric approach to the hip. Orthop Rev 1988; 17: 965-971.
43. van der Heide HJ, Koorevaar RT, Schreurs BW, van KA, Lemmens A. Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. J Arthroplasty 1999; 14: 796-799.
44. van Leeuwen WM, Deckers P, de Lange WJ. Pre-operative irradiation for prophylaxis of ectopic ossification after hip arthroplasty. A randomized study in 62 hips. Acta Orthop Scand 1998; 69: 116-118.
45. Vastel L, Kerboull L, Anract P, Kerboull M. Heterotopic ossification after total hip arthroplasty: risk factors and prevention. Rev Rhum Engl Ed 1998; 65: 238-244.
46. Weber EWG, Slappendel R, Durieux ME, Dirksen R, van der Heide HJ, Spruit M. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiologie 2003; 20: 963-966.
47. Wixson RL, Stulberg SD, Mehlhoff M. Total hip replacement with cemented, uncemented, and hybrid prostheses. A comparison of clinical and radiographic results at two to four years. J Bone Joint Surg 1991; 73-A: 257-270.
48. Wright JG, Moran E, Bogoch E. Reliability and validity of the grading of heterotopic ossification. J Arthroplasty 1194; 9: 549-553.
49. Wurnig C, Eyb R, Auersperg V. Indomethacin for prevention of ectopic ossification in cementless hip arthroplasties. A prospective 1-year study of 100 cases. Acta Orthop Scand 1992; 63: 628-630.